Gracell Biotechnologies Inc. (GRCL) — Financial Flexibility Index
Gracell Biotechnologies Inc. (GRCL) has a Financial Flexibility Index of -0.26x as of March 2021. Free cash flow of $-49.84 Million (operating CF $-63.95 Million minus capex $14.11 Million) represents 0% of total liabilities ($193.62 Million). Also explore Gracell Biotechnologies Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Gracell Biotechnologies Inc. Financial Flexibility Index (2018–2022)
Historical Financial Flexibility Index trend for Gracell Biotechnologies Inc. across 5 annual periods. Check Gracell Biotechnologies Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Gracell Biotechnologies Inc. (2018–2022)
Year-by-year free cash flow to debt coverage for Gracell Biotechnologies Inc.. For the full company profile including market capitalisation, see Gracell Biotechnologies Inc. (GRCL) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2022 | -10.61x | $-2.98 Billion | $-3.31 Billion | $280.51 Million | ▼ -896.4% |
| 2021 | -1.06x | $-247.81 Million | $-304.55 Million | $232.77 Million | ▼ -30.3% |
| 2020 | -0.82x | $-118.75 Million | $-198.15 Million | $145.29 Million | ▼ -62.4% |
| 2019 | -0.50x | $-78.96 Million | $-135.39 Million | $156.86 Million | ▼ -45.7% |
| 2018 | -0.35x | $-50.50 Million | $-61.86 Million | $146.13 Million | — |